Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS: PVCT · Delayed Price · USD
0.0900
-0.0050 (-5.26%)
Aug 30, 2024, 3:57 PM EDT - Market closed
PVCT Employees
Provectus Biopharmaceuticals had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$170,977
Profits / Employee
-$697,536
Market Cap
37.79M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
PVCT News
- 6 months ago - Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 6 months ago - Provectus Biopharmaceuticals, Inc. (PVCT) Q1 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call - GlobeNewsWire
- 7 months ago - Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services - GlobeNewsWire
- 9 months ago - Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant - GlobeNewsWire
- 10 months ago - Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma - GlobeNewsWire